Engine Biosciences
Engine Biosciences is a Singapore- and Silicon Valley-based biotech that uses its AI-powered NetMappr platform to map biological networks and develop precision oncology therapeutics for pharmaceutical partners and academic collaborators.
- Company typePrivate
- Founded2016
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Engine Biosciences does
Engine Biosciences is a Singapore-headquartered biotechnology company that applies machine learning and computational biology to precision oncology drug discovery. Founded in 2016, the company operates dual hubs in Singapore (corporate headquarters) and Silicon Valley (US research and development and partnerships), with a team of 11-50 employees. Its core technology is the NetMappr platform, which maps biological network relationships to identify and validate therapeutic targets in cancer. Built on this platform, Engine Biosciences is developing a portfolio of precision oncology drug candidates targeting specific disease mechanisms, pursuing a platform-plus-pipeline business architecture.
The company pursues a partnership-led go-to-market focused on pharmaceutical and biotechnology firms developing cancer therapeutics, alongside academic and research institutions. Revenue is generated through drug discovery collaborations, licensing agreements, co-development arrangements, milestone payments, and royalties — commercial terms are negotiated on a partnership-by-partnership basis and are not publicly disclosed. Marketing channels include direct partner engagement, scientific conferences, and academic collaborations rather than direct product sales. The company is pre-commercial: it has no approved products on the market and is still advancing its pipeline.
Engine Biosciences has raised over $100 million cumulatively across multiple funding rounds since 2018, including a $43 million Series A in May 2021 led by Polaris Partners — at the time the largest biotech Series A in Singapore. Lead institutional backers include Polaris Partners, EDBI, 6 Dimensions Capital, DHVC, Baidu Ventures, Invus, and WuXi AppTec. In 2026, Engine Biosciences was reported to be among firms considering a listing on the Hong Kong Stock Exchange as part of the broader Asian IPO rebound.
Engine Biosciences firmographics
Firmographics- Name
- Engine Biosciences
- Legal name
- Engine Biosciences
- Website
- https://enginebio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Engine Biosciences is a Singapore- and Silicon Valley-based biotech that uses its AI-powered NetMappr platform to map biological networks and develop precision oncology therapeutics for pharmaceutical partners and academic collaborators.
- Ownership category
- akta.pro rank
Engine Biosciences industry classification
Industry- Product category
- Precision Oncology Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Engine Biosciences is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices3 records
Markets served
Engine Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Drug Development and Licensing: Revenue generated through development of precision oncology therapeutics and licensing agreements with pharmaceutical partners. The company advances clinical programs and pursues collaborations in disease areas, potentially leading to milestone payments, royalties, and co-development arrangements.
- Platform Technology Partnerships: Partnerships leveraging the NetMappr platform for drug discovery collaborations with other biotechnology and pharmaceutical companies, generating revenue through research collaborations, service fees, and co-development agreements.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Engine Biosciences product offering
Product offeringCore offering
Engine Biosciences develops precision oncology therapeutics using its proprietary AI-powered NetMappr computational biology platform, which maps biological network relationships to identify and validate drug targets in cancer. The company operates a platform-plus-pipeline model, leveraging the NetMappr platform to discover targets and advance a portfolio of precision oncology drug candidates, while pursuing co-development and licensing agreements with pharmaceutical partners.
Product overview
Engine Biosciences operates as a precision oncology biotech company with a platform-plus-pipeline architecture. The core of their technology is the NetMappr computational biology platform, which maps biological network relationships to identify and validate drug targets. Built upon this platform, the company develops a portfolio of precision oncology therapeutics targeting specific disease mechanisms. The NetMappr platform serves as the foundational technology enabling the drug discovery and development programs.
Differentiator
Problem solved
Functional benefit
Products and services
- NetMappr Platform AI-powered computational biology platform that maps biological network relationships to identify and validate therapeutic targets for precision oncology drug discovery. Used by pharmaceutical and biotechnology partners in research collaborations and co-development agreements.
- Precision Oncology Therapeutics Portfolio A pipeline of precision oncology drug candidates developed internally using the NetMappr platform to target specific biological mechanisms in cancer. Licensed or co-developed with pharmaceutical partners under licensing, co-development, and milestone/royalty arrangements.
Companies that use Engine Biosciences
Customer profileSegments1 record
Ideal customer profiles1 record
Engine Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Engine Biosciences partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights4 records
Engine Biosciences competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Engine Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Engine Biosciences leadership team
Management profileNumber of profiles
Profiles3 records
Engine Biosciences funding detail
Funding detailFunding overview
Funding rounds9 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Engine Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Engine Biosciences
What does Engine Biosciences do?
Engine Biosciences develops precision oncology therapeutics using its proprietary AI-powered NetMappr computational biology platform, which maps biological network relationships to identify and validate drug targets in cancer. The company operates a platform-plus-pipeline model, leveraging the NetMappr platform to discover targets and advance a portfolio of precision oncology drug candidates, while pursuing co-development and licensing agreements with pharmaceutical partners.
Is Engine Biosciences a public or private company?
Engine Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Engine Biosciences founded?
Engine Biosciences was founded in 2016. It employs 11 to 50 people.
Where is Engine Biosciences based?
Engine Biosciences is headquartered in Singapore, Singapore, in the Asia region.
How does Engine Biosciences make money?
Two revenue lines are on record. Drug Development and Licensing is the primary driver. The others are platform Technology Partnerships.
Does Engine Biosciences have an API?
No public API is recorded for Engine Biosciences.
What industry is Engine Biosciences in?
Engine Biosciences's product category is Precision Oncology Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2836.